Chapter review

Fitzgerald PMHNP board review. ch02. Select Special Topics in Psychiatric-Mental Health Practice. This is drive 14 of 18. When I say Pause. Answer. wait, then I will give the answer. New section. Printed Fitzgerald Sample Question. Topic. Question 1 (Fitzgerald Sample Item). Of the following, which should be performed initially in assessing a 48-year-old woman with suicidal ideation? - A. Does she have someone at home to stay with her? - B. What is the content of her thoughts? - C. Does she have access to a firearm? - D. Has she attempted suicide in the past? Pause. Answer. B. Why it is correct: In assessing a patient presenting with suicidal ideation, assessing the content of her thoughts (determining active intent, plan, and ideation severity) is the mandatory initial assessment step to establish immediate clinical risk before evaluating external support or lethality factors. Why each distractor fails: - A. Evaluating home support is a safety planning intervention that occurs after completing the initial assessment of thought content and risk. - C. Assessing access to firearms is a crucial lethal means assessment, but assessing the immediate content of her suicidal thoughts comes first in the evaluation sequence. - D. Past suicide attempts represent an important historical risk factor, but assessing her current thought content and active intent takes immediate priority. Test-taking pearl: Assessment of current thought content and intent comes before secondary historical risk factors or outpatient disposition planning. Concept tested: Initial assessment sequence in psychiatric evaluation. Live Board Practice Items. Question 2. A 52-year-old male with no personal or family history of psychiatric illness presents to the outpatient clinic with a 3-week history of severe depressed mood, severe fatigue, psychomotor slowing, and constipation. He has not had a physical exam or blood work in five years. What is the PMHNP's most appropriate initial action? - A. Initiate **sertraline** 50 mg daily for **major depressive disorder**. - B. Order a complete blood count, comprehensive metabolic panel, and thyroid-stimulating hormone level to rule out physical mimics. - C. Refer the patient for cognitive behavioral therapy. - D. Administer the Hamilton Depression Rating Scale. Pause. Answer. B. Why it is correct: In a 52-year-old male presenting with first-onset depressed mood and no psychiatric history, the mandatory safety rule dictates ruling out physical mimics, such as hypothyroidism or anemia, with laboratory screening before establishing a primary psychiatric diagnosis or initiating psychotropics. Why each distractor fails: - A. Initiating an antidepressant before ruling out medical mimics like hypothyroidism mismanages a potential organic cause. - C. Psychotherapy is an evidence-based treatment for primary depression, but physical medical causes must be excluded first in late-onset presentations. - D. Administering a rating scale quantifies symptom severity, but does not fulfill the mandatory safety requirement to rule out underlying physical disease. Test-taking pearl: Late-onset psychiatric symptoms without prior psychiatric history require laboratory screening to rule out physical mimics before starting psychiatric treatment. Concept tested: Mandatory medical rule-out in late-onset depression. Question 3. An 8-year-old boy is brought for a psychiatric evaluation due to new-onset hyperactive behavior, inattention, and restlessness at school. His parents report that his symptoms began abruptly two weeks ago following a recovery from a fever and sore throat. Physical exam shows normal vital signs, but he exhibits sudden vocal throat-clearing tics. What is the PMHNP's priority diagnostic step? - A. Diagnose **attention-deficit/hyperactivity disorder** and prescribe **methylphenidate**. - B. Collaborate with the primary care provider to obtain throat culture, ASO titers, and anti-DNase B titers to evaluate for PANDAS. - C. Order a head CT scan to rule out a frontal lobe tumor. - D. Initiate **atomoxetine** 10 mg daily for non-stimulant ADHD management. Pause. Answer. B. Why it is correct: Abrupt, overnight onset of behavioral changes and tics following a sore throat is an atypical presentation indicating a post-streptococcal autoimmune physical mimic (PANDAS), requiring streptococcal antibody testing to guide antistreptococcal treatment before diagnosing primary ADHD. Why each distractor fails: - A. Diagnosing primary ADHD and starting stimulants without evaluating acute post-streptococcal tics and sudden onset mismanages an autoimmune medical mimic. - C. Head CT is not indicated for acute post-streptococcal tic emergence without focal neurological hard signs or acute head trauma. - D. Prescribing non-stimulants fails to address potential underlying streptococcal basal ganglia inflammation. Test-taking pearl: Sudden overnight onset of tics or behavioral changes following a sore throat dictates testing for streptococcal infection first. Concept tested: Rule-out of post-streptococcal autoimmune physical mimics. Question 4. A 68-year-old female presents with acute onset of severe anxiety, confusion, and visual hallucinations over 24 hours. She has a history of hypertension and osteoarthritis. Her temperature is 100.8 degrees Fahrenheit, heart rate is 104 beats per minute, and blood pressure is 148/92 mm Hg. Which action represents the PMHNP's most urgent priority? - A. Prescribe **lorazepam** 1 mg orally for acute anxiety and agitation. - B. Obtain a urinalysis, urine culture, complete blood count, and metabolic panel to evaluate for acute delirium secondary to infection. - C. Diagnose late-life **schizophrenia** and start **risperidone** 0.5 mg at bedtime. - D. Refer for an outpatient neuropsychological evaluation. Pause. Answer. B. Why it is correct: Acute onset of confusion, visual hallucinations, fever, and tachycardia in an older adult indicates medical delirium, most commonly caused by an underlying physical infection such as a urinary tract infection or pneumonia. Emergency laboratory evaluation to identify the physical cause is the mandatory safety rule. Why each distractor fails: - A. Benzodiazepines exacerbate non-withdrawal delirium, increasing confusion and fall risks without treating the underlying infection. - C. Schizophrenia does not present acutely with fever and fluctuating levels of consciousness in a 68-year-old. - D. Outpatient neuropsychological testing is inappropriate for an acute, unstable medical delirium. Test-taking pearl: Acute mental status changes with fever or abnormal vitals in older adults indicate medical delirium requiring urgent physical evaluation. Concept tested: Mandatory medical rule-out in acute delirium. Question 5. Which of the following statements represents the core safety rationale for mandating the rule-out of physical mimics prior to establishing a primary psychiatric diagnosis? - A. Psychotropic medications are completely ineffective whenever physical comorbidities exist. - B. Unrecognized physical medical conditions can cause irreversible organ damage or death if left untreated, and psychotropics can mask or exacerbate underlying physical disease. - C. Insurance guidelines prohibit prescribing psychiatric medications without documented laboratory panels. - D. Physical mimics only occur in geriatric populations over age 65. Pause. Answer. B. Why it is correct: The primary safety rationale for mandating medical rule-outs is that underlying physical illnesses (such as brain tumors, severe infections, thyroid storm, or toxicities) can be life-threatening if missed, and psychotropics can obscure physical symptoms or worsen organ failure. Why each distractor fails: - A. Psychotropics can affect neurochemistry even in medical conditions, but failing to treat the underlying physical disease allows pathology to progress dangerously. - C. Mandatory rule-out is a clinical safety rule based on standard of care and patient outcomes, not merely an administrative insurance requirement. - D. Physical mimics occur across all age groups, including children (PANDAS) and young adults (substance toxicity, thyroid disease). Test-taking pearl: Ruling out physical mimics protects patient safety by preventing missed diagnoses of treatable, life-threatening medical conditions. Concept tested: Safety rationale for mandatory physical rule-outs in psychiatric assessment. Best Next Step. Best next step. Move to the next parent section under FITZGERALD CH02 covering Endocrine mimics: Thyroid, adrenal, and glucose dysregulation to master identifying Addison disease, Cushing syndrome, hypoglycemia, and diabetic ketoacidosis as physical triggers of psychiatric symptoms for board certification. Next. Topic. Ordering Tests: Psychiatry frequently orders medical lab work. } Next. Topic. Screening Tools: WHO-DAS for disability assessment. Bottom Line. Bottom line. The World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) is a self-administered, 36-item tool that assesses global disability and functional impairment across six life domains, replacing the Global Assessment of Functioning (GAF) scale in DSM-5. Key Concepts on WHO-DAS 2.0. * Rationale and Origin: Developed by the World Health Organization based on the International Classification of Functioning, Disability and Health (ICF), WHODAS 2.0 provides a standardized, cross-culturally validated measure of disability across all medical and psychiatric conditions. * Six Assessment Domains: * Understanding and communicating (cognition and verbal processing) * Getting around (mobility and physical movement) * Self-care (hygiene, dressing, eating) * Getting along with people (interpersonal relationships and social interaction) * Life activities (domestic responsibilities, leisure, work, and school) * Participation in society (community engagement and civic life) * Replacement of GAF Scale: DSM-5 removed the clinician-rated Global Assessment of Functioning (GAF) score because it was overly subjective and conflated symptom severity with functional impairment. WHODAS 2.0 relies on patient self-report to evaluate functional disability independently of specific diagnostic categories. * Clinical Utility: WHODAS 2.0 is used during initial evaluation and periodically throughout treatment to measure baseline impairment, evaluate treatment progress, track functional recovery, and support disability determinations. Safety Alert. Safety alert. Never substitute a WHODAS 2.0 disability score for a comprehensive suicide risk assessment or acute safety evaluation. While WHODAS 2.0 quantifies functional impairment across life domains, it is a self-administered screening questionnaire and does not evaluate active suicidal intent, plan, lethality, or immediate psychiatric emergency risks. Board Trap. Board trap. Do not select the Global Assessment of Functioning (GAF) scale when asked about current DSM-5-TR functional disability assessment tools. GAF was retired due to inter-rater subjectivity. Additionally, do not assume WHODAS 2.0 is a diagnostic tool; it measures functional disability across life domains regardless of diagnosis, but does not establish a primary psychiatric diagnosis. First-Line. First-line. Your **first-line** application for WHODAS 2.0 is administering it as a self-reported baseline measure of functional disability when evaluating a patient with a psychiatric or medical condition, and repeating it at structured follow-up intervals to quantify treatment response and functional recovery. Compare and Distinguish. WHODAS 2.0 vs. Global Assessment of Functioning (GAF). * Think WHODAS 2.0 when: Self-administered tool assessing functional disability across six discrete domains (cognition, mobility, self-care, interpersonal, life activities, participation) in DSM-5 and DSM-5-TR. * Think GAF when: Clinician-rated Axis V score (0 to 100) from DSM-IV-TR that combined symptom severity with global functioning, now obsolete due to subjectivity. * Priority difference: WHODAS 2.0 separates functional disability from symptom severity, whereas GAF conflated both into a single subjective number. * What boards are testing: Recognizing that WHODAS 2.0 replaced GAF as the standardized DSM measure for functional disability. WHODAS 2.0 vs. Activities of Daily Living (ADL) / IADL Scales. * Think WHODAS 2.0 when: Patient self-administered 36-item tool measuring broad psychosocial, cognitive, communicative, and societal disability across all psychiatric and medical populations. * Think ADL / IADL Scales when: Informant- or clinician-administered tools (such as Katz ADL or Lawton IADL) specifically evaluating basic physical self-care (bathing, dressing) and complex community survival skills (managing finances, cooking) in neurocognitive disorders or geriatric patients. * Priority difference: WHODAS 2.0 provides a universal cross-cultural measure of functional disability across all age groups and conditions, whereas ADL/IADL scales target specific self-care tasks in cognitive or physical decline. * What boards are testing: Differentiating broad self-reported disability screening from targeted neurocognitive functional impairment scales. Next. Topic. Question 1 (Fitzgerald Sample Item). Complete the following statement regarding functional assessment: The self-administered assessment that measures disability across cognitive, interpersonal, work, and social domains is the: - A. Hamilton Rating Scale for Depression - B. World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) - C. Global Assessment of Functioning (GAF) scale - D. Brief Psychiatric Rating Scale (BPRS) Pause. Answer. B. Why it is correct: The WHODAS 2.0 is a self-administered assessment instrument that measures disability and functional impairment across six specific domains, including cognitive, interpersonal, work, and social domains, regardless of the patient's underlying health condition. Why each distractor fails: - A. The Hamilton Rating Scale for Depression (HAM-D) is a clinician-administered tool that quantifies depressive symptom severity, not global disability. - C. The Global Assessment of Functioning (GAF) scale was a clinician-rated tool in DSM-IV-TR that was replaced by WHODAS 2.0 in DSM-5. - D. The Brief Psychiatric Rating Scale (BPRS) measures general psychiatric and psychotic symptom severity rather than self-reported functional disability. Test-taking pearl: WHODAS 2.0 is the self-administered DSM-5 tool designed to assess functional disability across multiple life domains. Concept tested: Identification of WHODAS 2.0 as the self-administered disability assessment tool. Live Board Practice Items. Question 2. A 38-year-old female with major depressive disorder is completing an intake evaluation. The PMHNP requests that she complete the WHODAS 2.0 to establish a baseline of her functional impairment. Which of the following areas is directly evaluated as one of the six core domains on the WHODAS 2.0? - A. Substance use frequency and cravings - B. Getting along with people and interpersonal interactions - C. Pharmacological side effect burden - D. Active suicidal ideation and intent Pause. Answer. B. Why it is correct: Getting along with people (interpersonal relationships) is one of the six specific functional domains assessed by WHODAS 2.0, along with understanding and communicating, getting around, self-care, life activities, and participation in society. Why each distractor fails: - A. Substance use frequency is screened using tools like the AUDIT or CAGE, not WHODAS 2.0. - C. Medication side effects are evaluated using specific adverse effect scales like the AIMS, not WHODAS 2.0. - D. Suicidal ideation is assessed using dedicated risk assessment tools like the C-SSRS, not WHODAS 2.0. Test-taking pearl: Remember the six WHODAS 2.0 domains: understanding/communicating, mobility, self-care, getting along with people, life activities, and societal participation. Concept tested: Core domains of WHODAS 2.0. Question 3. Why did the American Psychiatric Association replace the Global Assessment of Functioning (GAF) scale with the WHODAS 2.0 in DSM-5? - A. GAF required expensive laboratory testing prior to administration. - B. GAF was excessively subjective and inappropriately combined symptom severity with functional impairment. - C. GAF could only be administered to pediatric populations under age 12. - D. WHODAS 2.0 is the only tool that establishes a formal psychiatric diagnosis. Pause. Answer. B. Why it is correct: The GAF scale was eliminated in DSM-5 because it lacked inter-rater reliability due to clinician subjectivity and conflated symptom severity with functional capacity. WHODAS 2.0 was adopted as an objective, self-administered tool that measures disability independently of symptom severity. Why each distractor fails: - A. Neither GAF nor WHODAS 2.0 requires laboratory testing. - C. GAF was used across all age groups in DSM-IV-TR. - D. WHODAS 2.0 measures functional disability but does not establish a psychiatric diagnosis. Test-taking pearl: WHODAS 2.0 replaced GAF to eliminate clinician subjectivity and separate disability from symptom severity. Concept tested: Rationale for adopting WHODAS 2.0 over GAF in DSM-5. Question 4. A 45-year-old male veteran with post-traumatic stress disorder reports that he feels completely unable to hold a job or participate in family events. The PMHNP uses the WHODAS 2.0 during follow-up visits. How does WHODAS 2.0 assist in tracking treatment progress? - A. It provides a standardized numeric measurement of functional disability that can be compared across treatment intervals. - B. It automatically calculates the exact dosage of psychotropic medication needed. - C. It determines whether the patient requires involuntary inpatient commitment. - D. It measures serum drug levels to ensure therapeutic compliance. Pause. Answer. A. Why it is correct: WHODAS 2.0 provides a standardized, objective baseline score across six life domains that can be repeated over time to track changes in functional recovery or disability in response to therapeutic interventions. Why each distractor fails: - B. WHODAS 2.0 measures disability and has no function in calculating medication dosages. - C. Involuntary commitment is based on immediate danger to self/others or grave disability, evaluated via clinical risk assessment, not WHODAS 2.0 scores alone. - D. WHODAS 2.0 is a self-report questionnaire, not a blood test for serum drug levels. Test-taking pearl: WHODAS 2.0 is used longitudinally to track objective improvements or decline in functional disability. Concept tested: Clinical utility of WHODAS 2.0 in monitoring treatment response. Best Next Step. Best next step. Move to the next parent section under FITZGERALD CH02 covering Endocrine mimics: Thyroid, adrenal, and glucose dysregulation to master identifying Addison disease, Cushing syndrome, hypoglycemia, and diabetic ketoacidosis as physical triggers of psychiatric symptoms for board certification. Next. New section. Pharmacology Safety. Topic. Bupropion (Wellbutrin): Strict seizure risk contraindication in EDs. } Next. Topic. Clozapine: Only FDA-approved med for suicide risk in Schizophrenia. Bottom Line. Bottom line. **Clozapine** is the only medication approved by the Food and Drug Administration (FDA) specifically to reduce the risk of recurrent suicidal behavior in patients with **schizophrenia** or **schizoaffective disorder**. While **lithium** reduces suicide risk in bipolar disorder, **clozapine** holds the unique FDA indication for suicide risk reduction in psychotic disorders. Beyond suicide prevention, **clozapine** is the gold-standard treatment for treatment-resistant **schizophrenia** after two failed antipsychotic trials. However, its use requires strict adherence to the **Clozapine REMS** monitoring protocol due to life-threatening risks of severe neutropenia, **agranulocytosis**, myocarditis, seizures, and paralytic ileus. Key Concepts on Clozapine and Suicide Risk in Schizophrenia. * Anti-Suicide Indication: **Clozapine** is FDA-approved to reduce suicidal behavior in **schizophrenia** and **schizoaffective disorder**. Clinical trial data (such as the InterSePT trial) demonstrate that **clozapine** significantly reduces suicidal thoughts, suicide attempts, and hospitalizations compared to other atypical antipsychotics like **olanzapine**. This anti-suicide effect is independent of its overall antipsychotic or sedative actions. * Gold Standard in Treatment-Resistant Schizophrenia: **Clozapine** is recommended as a third-line agent when a patient fails to respond to at least two adequate trials of other antipsychotic medications (including at least one second-generation antipsychotic). It improves both positive and negative symptoms and reduces persistent aggression and hostility. * **Clozapine REMS** and **Absolute Neutrophil Count (ANC)** Monitoring: * Baseline Requirement: Before starting **clozapine**, baseline **ANC** must be at least 1500/mm3 for the general population, or at least 1000/mm3 for patients with documented **benign ethnic neutropenia (BEN)**. White blood cell count alone is no longer used for decision-making under the updated REMS protocol. * Monitoring Schedule: **ANC** must be checked weekly for the first 6 months, then every 2 weeks for months 6 to 12, and monthly after 12 months for the duration of treatment. * Interruption Threshold: **Clozapine** must be interrupted if the **ANC** drops below 1000/mm3 in the general population (or below 500/mm3 in BEN patients), and hematology consultation should be initiated. * Other Critical Life-Threatening Adverse Effects: * **Myocarditis and Cardiomyopathy**: Most common in the first 6 weeks of treatment. Baseline troponin I or T and C-reactive protein (CRP) should be checked, and **clozapine** promptly discontinued if myocarditis is suspected (presenting with dyspnea, chest pain, or fever). * **Dose-Dependent Seizures**: **Clozapine** lowers the seizure threshold. Risk increases significantly at doses exceeding 600 mg daily or with rapid dose titration. * **Severe Constipation and Gastrointestinal Hypomotility**: Strong anticholinergic activity can cause severe constipation, paralytic ileus, bowel obstruction, and death. Proactive bowel regimens (such as docusate or polyethylene glycol) are routinely recommended. * **Sialorrhea (Excessive Drooling)**: Driven by alpha-2 adrenergic antagonism and M3 muscarinic receptor effects. Nighttime drooling can lead to choking and aspiration pneumonia; treated off-label with sublingual atropine drops or anticholinergics. * **Severe Cardiometabolic Risk**: Marked weight gain, hyperlipidemia, and severe hyperglycemia or new-onset type 2 diabetes. * Drug Interactions and Smoking Impact: Tobacco smoke byproducts (hydrocarbons, not nicotine) strongly induce the CYP1A2 hepatic enzyme. When a patient on **clozapine** stops smoking, CYP1A2 activity decreases, causing serum **clozapine** levels to spike rapidly, leading to toxicity and seizures. Conversely, starting or increasing smoking lowers **clozapine** blood levels, risking psychotic relapse. Safety Alert. Safety alert. Never ignore fever, sore throat, lethargy, or flu-like symptoms in a patient taking **clozapine**. These physical signs can signal impending **agranulocytosis** or severe neutropenia. Obtain an immediate stat **absolute neutrophil count (ANC)** and hold **clozapine** if **ANC** falls below 1000/mm3. Additionally, educate patients that quitting smoking abruptly while on **clozapine** can cause severe drug toxicity and seizures due to loss of CYP1A2 enzyme induction. Board Trap. Board trap. Do not confuse the anti-suicide indications for **lithium** and **clozapine**. On board exams, test writers frequently test whether you know which drug matches which primary diagnosis. If the patient has **bipolar disorder** and suicidal ideation, select **lithium**. If the patient has **schizophrenia** or **schizoaffective disorder** with persistent suicidal behavior, select **clozapine**. Furthermore, do not assume that white blood cell count (WBC) dictates **clozapine** discontinuation under current guidelines; decision-making is strictly governed by the **absolute neutrophil count (ANC)**. First-Line. First-line. Your **first-line** action when evaluating a patient with **schizophrenia** who expresses active suicidal ideation or has a history of suicide attempts is assessing immediate physical safety, establishing a safety plan, and evaluating if they meet criteria for **clozapine** therapy (such as treatment resistance or chronic suicidality) after obtaining a baseline **absolute neutrophil count (ANC)** of at least 1500/mm3. Compare and Distinguish. Clozapine vs. Lithium Anti-Suicide Indications. * Think Clozapine when: The patient has a primary diagnosis of **schizophrenia** or **schizoaffective disorder** with chronic risk for suicidal behavior or treatment resistance. * Think Lithium when: The patient has a primary diagnosis of **bipolar disorder** or major mood disorder with recurrent suicidal ideation or attempts. * Priority difference: Both drugs reduce suicide risk independently of mood or psychotic stabilization, but **clozapine** requires **Clozapine REMS** **ANC** monitoring, whereas **lithium** requires serum drug levels, renal function tests, and thyroid monitoring. * What boards are testing: Matching the specific FDA-approved anti-suicide medication to the correct primary psychiatric diagnosis. Benign Ethnic Neutropenia (BEN) vs. Clozapine-Induced Agranulocytosis. * Think Benign Ethnic Neutropenia (BEN) when: A patient of African, Middle Eastern, or West Indian descent has a chronically lower baseline **ANC** (between 1000/mm3 and 1400/mm3) without an increased risk of infection or bone marrow suppression. * Think Clozapine-Induced Agranulocytosis when: An acute, dangerous drop in **ANC** occurs (below 500/mm3) due to drug-induced bone marrow suppression, presenting with high fever, rigors, and sore throat. * Priority difference: BEN patients can safely start **clozapine** with a lower baseline **ANC** cutoff (1000/mm3), whereas **clozapine** must be stopped immediately if agranulocytosis develops. * What boards are testing: Differentiating normal genetic neutrophil variations from life-threatening medication toxicity. Next. New section. Printed Fitzgerald Sample Question. Topic. Question 1 (Fitzgerald Sample Item). When considering the use of clozapine, regular monitoring of which of the following is required? - A. AST / ALT - B. Absolute neutrophil count (ANC) - C. Blood urea nitrogen (BUN) - D. Platelet count Pause. Answer. B. Why it is correct: **Clozapine** requires mandatory regular monitoring of the **absolute neutrophil count (ANC)** under the **Clozapine REMS** program to detect and prevent severe neutropenia and life-threatening **agranulocytosis**. Why each distractor fails: - A. AST and ALT assess hepatic function and are routinely monitored with **valproate**, not as part of the primary **clozapine** safety protocol. - C. BUN assesses renal function and is routinely monitored with **lithium**, not **clozapine**. - D. Platelet counts are monitored with **valproate** due to risk of thrombocytopenia, whereas **clozapine** specifically targets neutrophils. Test-taking pearl: **Clozapine** monitoring is exclusively governed by the **absolute neutrophil count (ANC)**. Concept tested: Mandatory lab monitoring for **clozapine**. Live Board Practice Items. Question 2. A 28-year-old male with a 6-year history of **schizophrenia** has failed adequate trials of **risperidone** and **olanzapine**. During his clinic visit, he expresses persistent auditory command hallucinations telling him to end his life, and his family reports two suicide attempts in the past year. Which medication is the only FDA-approved agent specifically indicated to reduce the risk of recurrent suicidal behavior in this patient? - A. **Lithium** - B. **Clozapine** - C. **Aripiprazole** - D. **Haloperidol** Pause. Answer. B. Why it is correct: **Clozapine** is the only FDA-approved medication for reducing the risk of recurrent suicidal behavior in patients with **schizophrenia** or **schizoaffective disorder**. Why the other choices are wrong: - A. **Lithium** reduces suicide risk in **bipolar disorder**, but is not FDA-approved for suicide risk reduction in **schizophrenia**. - C. **Aripiprazole** is a second-generation antipsychotic used in schizophrenia, but does not carry an FDA indication for suicide risk reduction. - D. **Haloperidol** is a first-generation antipsychotic that reduces positive psychotic symptoms but lacks an anti-suicide indication. Test-taking pearl: **Clozapine** is the single FDA-approved medication for reducing suicide risk in **schizophrenia**. Concept tested: FDA indications for suicide risk reduction in psychotic disorders. Question 3. A PMHNP is preparing to initiate **clozapine** for a 32-year-old female with treatment-resistant **schizophrenia**. The patient belongs to the general population with no history of neutropenia. Which baseline **absolute neutrophil count (ANC)** level is required to safely initiate **clozapine** therapy? - A. **ANC** equal to or greater than 500/mm3 - B. **ANC** equal to or greater than 1000/mm3 - C. **ANC** equal to or greater than 1500/mm3 - D. **ANC** equal to or greater than 3500/mm3 Pause. Answer. C. Why it is correct: According to the **Clozapine REMS** guidelines, a baseline **ANC** of at least 1500/mm3 is required to initiate **clozapine** therapy in the general population. Why the other choices are wrong: - A. An **ANC** below 500/mm3 represents severe neutropenia and requires immediate treatment interruption and hospitalization. - B. An **ANC** of 1000/mm3 is the baseline cutoff for patients with documented **benign ethnic neutropenia (BEN)**, not the general population. - D. A value of 3500/mm3 was an older historical white blood cell (WBC) count threshold, not the current **ANC** requirement. Test-taking pearl: Remember baseline **ANC** cutoffs: 1500/mm3 for the general population and 1000/mm3 for benign ethnic neutropenia. Concept tested: Baseline lab parameters for **clozapine** initiation. Question 4. A 35-year-old male taking **clozapine** 400 mg daily for **schizophrenia** presents for a routine follow-up visit. His blood work demonstrates an **absolute neutrophil count (ANC)** of 850/mm3. He has no fever or signs of infection. What is the PMHNP's priority action? - A. Continue **clozapine** at the current dose and recheck **ANC** in one month. - B. Interrupt **clozapine** treatment immediately and monitor **ANC** closely. - C. Increase the **clozapine** dose to 500 mg daily. - D. Add **lithium** to boost the white blood cell count while continuing **clozapine**. Pause. Answer. B. Why it is correct: An **ANC** below 1000/mm3 in the general population requires immediate interruption of **clozapine** therapy to prevent progression to fatal **agranulocytosis**. Why the other choices are wrong: - A. Continuing **clozapine** with an **ANC** below 1000/mm3 exposes the patient to severe infection and death. - C. Increasing the dose worsens bone marrow suppression and toxicity. - D. While **lithium** can cause benign leukocytosis, holding **clozapine** takes immediate priority when **ANC** falls below 1000/mm3. Test-taking pearl: Interrupt **clozapine** immediately whenever **ANC** drops below 1000/mm3 in the general population. Concept tested: Managing neutropenia during **clozapine** therapy. Question 5. A 40-year-old male with **schizophrenia** has been successfully stabilized on **clozapine** 300 mg daily for 2 years. During a follow-up visit, he mentions that he quit his 2-pack-a-day cigarette smoking habit 3 days ago using nicotine patches. Why does this lifestyle change require urgent clinical attention by the PMHNP? - A. Nicotine patches block **clozapine** absorption in the gastrointestinal tract. - B. Cessation of tobacco smoke removes CYP1A2 induction, causing serum **clozapine** levels to rise rapidly and increasing seizure risk. - C. Quitting smoking causes rapid renal clearance of **clozapine**, leading to psychotic relapse. - D. Nicotine withdrawal causes severe **agranulocytosis** when combined with **clozapine**. Pause. Answer. B. Why it is correct: Hydrocarbons in tobacco smoke induce the CYP1A2 enzyme. When a patient stops smoking, CYP1A2 activity decreases, leading to elevated serum **clozapine** levels and a high risk of side effects, sedation, and seizures. Why the other choices are wrong: - A. Nicotine replacement therapy does not interfere with oral drug absorption. - C. Cessation of smoking increases drug levels, not renal clearance. - D. Smoking cessation alters hepatic metabolism but does not directly cause bone marrow **agranulocytosis**. Test-taking pearl: Stopping smoking increases **clozapine** levels; starting smoking decreases **clozapine** levels. Concept tested: Drug interactions and metabolic shifts with **clozapine** and smoking. Best Next Step. Best next step. Move to the next parent section under FITZGERALD CH02 covering Special populations and practice settings called out in this chapter to master pediatric, geriatric, pregnant, and correctional mental health topics for board certification. Next. Topic. LAIs: Relapse prevention for schizophrenia patients. Bottom Line. Bottom line. Nonadherence to oral antipsychotics is the single greatest cause of relapse, rehospitalization, and progressive cognitive decline in patients with **schizophrenia**. Long-acting injectable (LAI) antipsychotics eliminate covert nonadherence, maintain steady therapeutic plasma levels, and significantly reduce illness relapse rates to under 30% per year. Transitioning to an LAI should be considered early in treatment, including during a first episode of psychosis, rather than reserving LAIs solely for chronic treatment resistance. Key Concepts on Long-Acting Injectables (LAIs) for Relapse Prevention. * Relapse Prevention Rationale: Each psychotic relapse in **schizophrenia** causes neurobiological damage, baseline functional deterioration, and increased treatment refractoriness. LAIs provide predictable bioavailability, eliminate daily pill burdens, and alert clinicians immediately when a dose is missed. * First-Generation Antipsychotic (FGA) LAIs: * **Haloperidol decanoate** (**Haldol Decanoate**) and **fluphenazine decanoate** (**Prolixin Decanoate**). * Formulated in a viscous sesame oil base requiring deep intramuscular (IM) administration using the Z-track technique with a dry, 21-gauge needle. The injection site must not be massaged. * Carry a higher risk of extrapyramidal symptoms (EPSEs), drug-induced parkinsonism, and **tardive dyskinesia** compared to second-generation LAIs. * Second-Generation Antipsychotic (SGA) LAIs: * **Risperidone microspheres** (**Risperdal Consta**): Administered IM every 2 weeks. Requires 3 to 4 weeks of oral **risperidone** overlap because drug release from polymer microspheres is delayed. * **Paliperidone palmitate**: * **Invega Sustenna** (once monthly IM): Initiated with two deltoid loading doses (150 mg on Day 1, 100 mg on Day 8) to rapidly achieve therapeutic levels without requiring oral medication overlap. * **Invega Trinza** (every 3 months IM): Approved only after a patient is clinically stabilized on once-monthly **Invega Sustenna** for at least 4 consecutive months. * **Invega Hafyera** (every 6 months IM): Approved for patients stabilized on 1-monthly or 3-monthly paliperidone formulations. * **Aripiprazole monohydrate** (**Abilify Maintena**) (once monthly IM) and **aripiprazole lauroxil** (**Aristada**) (every 4 to 8 weeks IM): Require 14 to 21 days of oral **aripiprazole** overlap unless initiated with specific single-day oral and IM loading combinations. * **Olanzapine pamoate** (**Zyprexa Relprevv**): Administered every 2 to 4 weeks IM. Requires strict monitoring under the **Zyprexa Relprevv REMS** program. Safety Alert. Safety alert. **Olanzapine pamoate** (**Zyprexa Relprevv**) carries a black box warning for **post-injection delirium sedation syndrome (PDSS)**, caused by accidental intravascular entry of the drug. Symptoms include severe sedation, confusion, dizziness, dysarthria, ataxia, and loss of consciousness occurring within 3 hours of injection. Under the **Zyprexa Relprevv REMS** protocol, the patient must be observed at a healthcare facility by a healthcare professional for at least 3 hours post-injection and must be accompanied home by an adult. Board Trap. Board trap. Do not forget oral medication overlap when starting **Risperdal Consta**. On board exams, test writers expect you to know that **risperidone** LAI takes 3 to 4 weeks to reach therapeutic blood levels, making oral **risperidone** coverage mandatory during initiation. Conversely, do not prescribe oral overlap for **Invega Sustenna**, which relies on Day 1 and Day 8 deltoid loading injections to achieve rapid therapeutic levels. First-Line. First-line. Your **first-line** intervention when evaluating a patient with **schizophrenia** who experiences frequent psychotic relapses or rehospitalizations due to partial or full medication nonadherence is establishing oral tolerability first, then transitioning the patient to a second-generation long-acting injectable (LAI) antipsychotic. Compare and Distinguish. Risperidone LAI (Risperdal Consta) vs. Paliperidone LAI (Invega Sustenna). * Think Risperidone LAI (Risperdal Consta) when: Administering an IM injection every 2 weeks that requires 3 to 4 weeks of oral **risperidone** overlap due to delayed microsphere release. * Think Paliperidone LAI (Invega Sustenna) when: Administering an IM injection once monthly that requires no oral overlap, using deltoid loading doses on Day 1 (150 mg) and Day 8 (100 mg). * Priority difference: **Invega Sustenna** eliminates the risk of nonadherence during the initiation phase by avoiding reliance on oral supplementation. * What boards are testing: Differentiating oral overlap requirements and administration schedules among second-generation LAIs. Zyprexa Relprevv (Olanzapine Pamoate) vs. Abilify Maintena (Aripiprazole). * Think Zyprexa Relprevv when: Selecting an LAI that carries a black box warning for **post-injection delirium sedation syndrome (PDSS)** and mandates 3 hours of post-injection medical observation under REMS. * Think Abilify Maintena when: Selecting a once-monthly partial dopamine agonist LAI with low metabolic risk that requires 14 days of oral **aripiprazole** overlap without post-injection REMS observation. * Priority difference: **Zyprexa Relprevv** carries heavy REMS logistical requirements due to PDSS, whereas **Abilify Maintena** requires no post-injection waiting period. * What boards are testing: Identifying the specific black box warning and REMS observation rules for **olanzapine pamoate**. Next. End of this drive.